Zai Lab (09688) has announced its financial results for the third quarter of 2026, reporting total revenue of $108.2 million, compared to $116.1 million in the same period of 2025.

Net product revenue for the third quarter of 2026 came in at $107.6 million, down from $115.4 million a year earlier. On a sequential basis, net product revenue grew 2%, driven primarily by Nuzyra (benefiting from expanded market coverage and penetration) and xanomeline trospium chloride (launched in June 2026), partially offset by a decline in Tumor Treating Fields revenue due to shifts in the competitive landscape for glioblastoma.

Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab, commented: "As we continue to advance our first wave of internally developed innovative medicines for patients globally, Zai Lab is entering a decisive phase of growth. The strong data presented at ESMO for zocilurtatug pelitecan (zoci) in first-line combination therapy reinforce our confidence in its potential to become a cornerstone ADC for small cell lung cancer. 2027 will be a pivotal year, as we expect to submit our first Biologics License Application (BLA) for zoci in the United States and continue advancing our first-line registrational development strategy for small cell lung cancer. Beyond zoci, ZL-1503 is our second global program, targeting one of the largest opportunities in immunology 鈥?atopic dermatitis. Together with our China business, which has achieved commercial profitability and is expected to return to growth in 2027, these advances will help Zai Lab create greater value for patients and shareholders."

Dr. Rafael G. Amado, President and Global Head of R&D at Zai Lab, stated: "In first-line small cell lung cancer, zoci at 1.6 mg/kg in combination with atezolizumab achieved a confirmed response rate of 81.8% and a 6-month progression-free survival rate of 81.9%. The data are encouraging and the treatment was well tolerated. This profile supports advancing a chemotherapy-free standard-of-care regimen into a global Phase 3 study and provides a solid foundation for our subsequent exploration of combinations with T-cell engagers. Our registrational programs in small cell lung cancer and neuroendocrine carcinoma are progressing toward key data readouts that could support our first BLA submission in the United States in 2027. In atopic dermatitis, ZL-1503 is designed to simultaneously block two disease-driving factors: IL-13, which causes inflammation, and IL-31R伪, which causes itching, and its half-life properties may support less frequent dosing. We will present first-in-human data at the ACAAI annual meeting in November and initial patient data in the first half of 2027. In addition, we expect two additional oncology and immunology programs to enter clinical development in 2027."